Effect of Tongxinluo capsule combined with atorvastatin on the expression of MMP-9, ET-1 and hs-CRP in patients with angina pectoris / 中国基层医药

ABSTRACT

Objective:To investigate the therapeutic effect of Tongxinluo capsule combined with atorvastatin in the treatment of angina pectoris and its effect on the expression of matrix metalloproteinase-9 (MMP-9), endothelin-1 (ET-1) and high sensitive C-reactive protein (hs-CRP).Methods:From September 2017 to September 2019, 174 patients with coronary heart disease and angina pectoris in the First People's Hospital of Hangzhou were divided into control group and treatment group according to the random digital table method, with 87 cases in each group.The treatment group was treated with Tongxinluo capsule and atorvastatin, while the control group was treated with atorvastatin.The course of treatment in both two groups was 12 weeks.The number of angina pectoris attack, angina pectoris attack time, MMP-9, ET-1 and hs-CRP levels were compared between the two groups before treatment and 12 weeks after treatment.Results:The number of angina attacks in the observation group was (2.17±0.67)times/week, which was lower than that in the control group [(3.41±0.52)times/week] ( t=13.637, P<0.05). The duration of angina pectoris in the observation group [(1.72±0.43)min/time] was lower than that in the control group [(2.89±0.56)min/time] ( t=14.457, P<0.05). The plasma MMP-9[(236.21±37.49)μg/L], ET-1[(43.57±8.10)ng/L] and hs-CRP [(2.64±0.41)mg/L] in the observation group were lower than those in the control group [(328.39±45.21) μg/L, (58.73±5.46)ng/L and (3.82±0.56)mg/L] ( t=14.693, 14.476, 15.858, all P<0.05). The total effective rate of the observation group (91.95%) was higher than that of the control group (78.16%) (χ 2=6.511, P<0.05). The incidence of adverse reactions in the observation group (8.05%) was lower than that in the control group (20.69%)(χ 2=5.652, P<0.05). Conclusion:Tongxinluo capsule combined with atorvastatin is effective in the treatment of angina pectoris of coronary heart disease.It can reduce the levels of MMP-9, ET-1 and hs-CRP in plasma, and has no obvious adverse reactions.